


Re-inventing access to biologics

Brussels, July 2023



Univercells develops breakthrough technologies and services that democratize the production of biologics.

So that everyone, everywhere has access to the medicines they need, when they need them.

Univercells widens access to biologics through innovative technology, manufacturing and advisory services

COMPANY HIGHLIGHTS

- ✓ Portfolio of disruptive bioproduction technology in viral vector & DNA/RNA
- ✓ Fully deployed state-of-the-art CDMO
- ✓ Adequate structure to open new markets and drive future innovation



R&D & cGMP facility ~10k m²

Budget 2023 Revenues¹ EUR +20 m

FTEs¹ ~400

Selected partnerships

BILL & MELINDA GATES foundation



Technology

Quantom Biosciences

RNA



Scalable platform and reagents to produce DNA/RNA

11
POs signed after
3 months of
Ntensify launch

1st
Installation at
Afrigen (WHO
mRNA hub)

CDMO

exothera



Cutting-edge facilities for viral vector and nucleic acids development and manufacturing, south of Brussels

<1.5y
to GMP
accreditation

17
Projects
executed in 2022

Advisory

RLM consulting

unizima



Services from technology transfer to regulatory affairs for emerging players to make biologics available to all

12
Active
countries

20
Active contracts
/ clients

Univercells serves many market segments across biologics through integrated solutions and services across three areas

GROUP – TECHNOLOGY – CDMO – ADVISORY



TECHNOLOGY

- **Development & industrialization** of intensified and scalable technology portfolio to enable partners to achieve **low cost, low footprint, high-quality and high-performance production**
- Applications in **DNA and RNA** from **R&D to commercial**

RNA




CDMO

- Designing and operating bespoke **bioproduction hubs with state-of-the-art technology** (including proprietary biomanufacturing technologies)
- Product & process development expertise for therapy innovators in C>, vaccines, DNA/RNA across all phases: from pre-clinical to GMP manufacturing and tech transfer



ADVISORY

- Opening new markets by providing turnkey services to **support emerging players** wherever biologics can make a difference, making **local bioproduction a reality**
- From **design to operations** of bioproduction sites, tech transfer, workforce development, product licenses and regulatory affairs



Univercells develops biomanufacturing technologies based on proven intensification & chaining fundamentals

GROUP – TECHNOLOGY – CDMO – ADVISORY

UNIVERCELLS ENGINEERING APPROACH



INTENSIFICATION

for high performance operations



CHAINING

of unit operations for automated, integrated & continuous processing

R&D ----- Scale-up -----> GMP ----- Scale-up -----> Commercial

Nfinity™ platform - Technologies and reagent pre-mixes to deliver formulated RNA from DNA at all development stages



Nplify

Cell-free DNA production



Ntensify™ Mini

R&D system
Dual application for drug discovery and pre-clinical phase



Ntensify™ Midi

Clinical Phases & annual production



Ntensify™ Maxi

Clinical Phase III & Commercial Production

0,5 mg

100 mg

< 1 day

Capacity (Drug Substance) /batch¹

1 g

5 g

Max. 1 day

12 g


1 day

73 g

6 days

Univercells delivered a high-performing disruptive viral vector biomanufacturing technology and replicated this success in DNA/RNA

GROUP – TECHNOLOGY – CDMO – ADVISORY



Univercells was selected as key technology partner by the WHO for the mRNA vaccine transfer hub aiming at locally produced & owned mRNA

GROUP – TECHNOLOGY – CDMO – ADVISORY



Paving the way for development of
1st African-owned COVID-19 vaccine



José Castillo
Co-Founder



Petro Terblanche
CEO




Bernard Sagaert
COO



Univercells as mRNA **technology partner** to **supercharge access** to affordable mRNA vaccines

15 selected spokes in LMICs, with Afrigen as pioneer central hub



We have invested in proprietary infrastructure, leveraging our technology background to offer customers unparalleled expertise

GROUP – TECHNOLOGY – CDMO – ADVISORY

TECHNOLOGY

RNA



VV



CDMO



Viral vector CDMO

Using standard and innovative bioproduction platforms to rapidly deliver affordable viral vector-based vaccines and cell and gene therapies



Nucleic Acids CRDMO

Leveraging an optimal process that can take your therapeutic at high quality and high speed from discovery up to production

BIOPROCESSING EXPERTISE AND PLATFORMS



exoREADY™
Viral vectors



exoREADY™
Nucleic acids

Adapted approach to customer's needs, delivering complex projects more quickly and cost-effectively for viral vectors and nucleic acids

GROUP – TECHNOLOGY – CDMO – ADVISORY

At Exothera it's not just what we do but how we do it that makes us different

Capability stack



State-of-the-art facilities

Scalable platforms in one facility from pre-clinical to GMP manufacturing for viral vector and nucleic acid production



Technology

The choice of cutting-edge suspension or adherent cell culture technologies for viral vectors & scalable platform for nucleic acids



Expertise

~150 experts in process development and viral vector/RNA manufacturing, having developed ground-breaking technologies



Quality driven

Every stage of the process is designed with quality in mind



Agility


Tailored and highly responsive, focusing on our clients' needs

17,000m² unique CDMO facilities were deployed in record time and received GMP certification in 2022



Our advisory services provide support to emerging players, expanding biomanufacturing capacity globally & building our future customer base

GROUP – TECHNOLOGY – CDMO – ADVISORY (Case Study)



Protect public health security by establishing a sustainable vaccine development and manufacturing ecosystem in Africa

Madiba² project set-up & roll-out

Planning, procurement, local recruitment & workforce development support

NevoLine technology platform used for low-cost production of MR for local needs



Project management

Operational Readiness

MR³ Tech Transfer

BILL & MELINDA GATES foundation



300m doses/year




Madiba: first modular & flexible vaccine manufacturing facility in Africa for pandemic & global health needs

Biologics available to all!



Contact Us

 **Univercells HQ**
All. Centrale - Zoning de
Jumet 52, 6040 Charleroi

 info@univercells.com

This report has been produced by Univercells in July 2023.

While the information provided herein is believed to be accurate, Univercells makes no representation or warranty, express or implied, as to the accuracy or completeness of such information. The information contained herein was prepared expressly for use herein and is based on certain assumptions and information available at the time this report was prepared. There is no representation, warranty or other assurance that any of the projections or estimates will be realized, and nothing contained within this report is or should be relied upon as a promise or representation as to the future. In furnishing this report Univercells reserves the right to amend or replace the report at any time and undertakes no obligation to provide the users with access to any additional information.